Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03093155 | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab | completed | Phase 2 | 78 | Yale UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT04823065 | 4FMFES-PET Imaging of Endometrial and Ovarian Cancers | completed | Phase 1 / Phase 2 | 53 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT01439490 | FES-PET to Determine ER-expression in Epithelial Ovarian Cancer | completed | Phase 2 | 15 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03572387 | A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment | completed | Phase 2 | 14 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT01088347 | Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer | completed | Phase 1 / Phase 2 | 9 | University Medical Center GroningenOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04028388 | ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer | completed | Phase 2 | 135 | Modra PharmaceuticalsINDUSTRY | 6 | Apr 17, 2024 | clinicaltrials |
| NCT04089553 | An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer | completed | Phase 2 | 59 | AstraZenecaINDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03148795 | A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 128 | PfizerINDUSTRY | 14 | Apr 5, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT02325557 | ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC) | completed | Phase 1 / Phase 2 | 50 | Advaxis, Inc.INDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03311555 | A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) | completed | Phase 2 | 39 | Andrew J. Armstrong, MDOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT01759771 | Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial(VD3PCa) | completed | Phase 2 | 130 | VA Office of Research and DevelopmentFED | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT04224740 | Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer(HERCULES) | completed | Phase 2 | 37 | Latin American Cooperative Oncology GroupOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT03189446 | Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer | completed | Phase 2 | 39 | University of OklahomaOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT02280356 | Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer | completed | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT01001910 | Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 22 | Albert Einstein College of MedicineOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02766582 | Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | completed | Phase 2 | 29 | Medical College of WisconsinOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT02901899 | Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 45 | Northwestern UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03554317 | COMbination of Bipolar Androgen Therapy and Nivolumab(COMBAT-CRPC) | completed | Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03936270 | Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer | completed | Phase 2 | 43 | Latin American Cooperative Oncology GroupOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03388346 | 68Ga PSMA in Preprostatectomy Patients | completed | Phase 2 / Phase 3 | 22 | Michael Graham PhD, MDOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03476798 | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium(Clovis-001) | completed | Phase 2 | 49 | University of OklahomaOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT00946881 | Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 30 | Steba Biotech S.A.OTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT02903160 | Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | completed | Phase 2 | 40 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03651271 | Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer | completed | Phase 2 | 100 | Parker Institute for Cancer ImmunotherapyOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03015129 | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | completed | Phase 2 | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03878823 | Safety and Pharmacokinetics of ODM-209(STESIDES) | completed | Phase 1 / Phase 2 | 38 | Orion Corporation, Orion PharmaINDUSTRY | 3 | Feb 1, 2024 | clinicaltrials |
| NCT02543255 | Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)(ACDC-RP) | completed | Phase 2 | 76 | University Health Network, TorontoOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT03698370 | Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer | completed | Phase 2 | 27 | Andrei IagaruOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03949517 | 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy | completed | Phase 1 / Phase 2 | 14 | Andrei IagaruOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT06226350 | A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma | completed | Phase 2 | 29 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jan 26, 2024 | clinicaltrials |
| NCT03117933 | Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer(OCTOVA) | completed | Phase 2 | 139 | University of OxfordOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT01704274 | GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy(GTN) | completed | Phase 2 | 43 | Dr. D. Robert SiemensOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02865135 | Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | completed | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT03809078 | 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer | completed | Phase 2 | 14 | Andrei IagaruOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04212377 | Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients(DECENDO) | completed | Phase 2 | 8 | Radboud University Medical CenterOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02915523 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer | completed | Phase 1 / Phase 2 | 140 | Syndax PharmaceuticalsINDUSTRY | 1 | Jan 10, 2024 | clinicaltrials |
| NCT04590599 | A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy | completed | Phase 2 | 205 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04284852 | Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting(NEOPRIMA) | completed | Phase 2 | 20 | The University of Hong KongOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT04405349 | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | completed | Phase 2 | 52 | Nykode Therapeutics ASAINDUSTRY | 6 | Dec 15, 2023 | clinicaltrials |
| NCT03113617 | 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer | completed | Phase 2 | 44 | Andrei IagaruOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | completed | Phase 1 / Phase 2 | 88 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT00915122 | Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate | completed | Phase 1 / Phase 2 | 81 | University Health Network, TorontoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT00818623 | Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients | completed | Phase 2 | 172 | Ferring PharmaceuticalsINDUSTRY | 7 | Nov 30, 2023 | clinicaltrials |
| NCT00819156 | Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer | completed | Phase 2 | 189 | Ferring PharmaceuticalsINDUSTRY | 8 | Nov 30, 2023 | clinicaltrials |
| NCT03367923 | Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors | completed | Phase 2 | 47 | Stanford UniversityOTHER | 1 | Nov 28, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 14, 2024source: clinicaltrials